A much cheaper insulin just launched, but it still might not help the most vulnerable

Mylan announced Monday that it was launching a new biosimilar insulin for Sanofi’s blockbuster insulin Lantus. It seemed like fantastic news for insulin affordability advocates: Mylan plans to sell its product for $98 a vial, while a vial of Lantus retails for more than $280. But as my colleague Ed Silverman writes, it’s still unclear whether the new, cheaper, product will make a big difference for patients with insurance. After all, insurers will have to choose to cover the biosimilar version, and insurers have been strikingly reluctant to cover biosimilars, which often offer smaller rebates. For more, check out Ed’s story here.